Company intelligence / Profile preview

Elute

Salt Lake City, Utah, United Stateselutinc.com ↗

Ownership: Private
Employees: ~7
Development stage: Commercial

Overview

BonVie+ received FDA clearance in March 2025 as a synthetic resorbable bone void filler. The lead investigational product, EP Granules with Tobramycin, delivers antibiotics locally over eight weeks and supports new bone growth. A pivotal clinical study was authorized by the FDA under an IDE for periprosthetic joint infections.

Therapeutic areas: OtherInfectious Diseases
Modalities: DevicePolymer-drug conjugate therapy (for drug-eluting devices)Small molecule (antibiotic payloads such as tobramycin)
Industry: Implantable Medical Devices

Drug pipeline

2 assets

BonVie+

Commercial

Indications: Bone loss, Bone defects

1 more asset in the full pipeline.

Request access →

Partnerships

Hospital for Special Surgery (HSS)Rothman Institute/Jefferson University Hospital

Beyond the preview

Go deeper on Elute.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Elute.

Explore the full profile